Tuberculosis preventive therapy : An underutilised strategy to reduce individual risk of TB and contribute to TB control by Churchyard, G J et al.
FORUM
339       May 2014, Vol. 104, No. 5
Burden of tuberculosis (TB) 
disease
TB remains a global health problem with an 
estimated burden of disease in 2012 of 8.6 million 
new cases, 13% co-infected with HIV, and an 
estimated 1.3 million TB deaths.[1] South Africa (SA) has one of the 
world’s worst TB epidemics, with the highest TB incidence among 
the 22 highest TB burden countries in the world, estimated at 933/ 
100 000 population in 2012, the third-largest absolute number of cases 
and the largest number of HIV-associated TB cases.[1] Approximately 
65% of TB patients in SA are HIV-infected.[1]
Burden of latent TB infection (LTBI)
The World Health Organization (WHO) estimated in 1999 that one-
third of the world’s population is latently infected with Mycobacterium 
tuberculosis.[2] The greatest burden of LTBI is in South-East Asia 
(46%), the Western Pacific region (32%), Africa (31%) and the 
Eastern Mediterranean region (27%).[3] Sub-Saharan Africa, however, 
has the largest number of persons with LTBI who are co-infected 
with HIV. In high-transmission settings such as SA, up to 88% of 
HIV-uninfected young adults (31 - 35 years) are latently infected 
with TB, and 89% of SA goldminers are TB-infected.[4-7] These data 
suggest that the burden of LTBI in SA is enormous. The prevalence 
of tuberculin skin test (TST) positivity among people co-infected 
with HIV is estimated to be 22.8% overall and highest among those 
with CD4+ counts ≥500 cells/µl (37.4%).[8] This is explained by the 
compromised ability of HIV-infected persons to react to the skin test 
because of cutaneous anergy associated with immunosuppression.
Risk of TB disease
LTBI occurs when individuals infected with M. tuberculosis harbour 
the organism in a latent state, characterised by slowed or intermittent 
metabolism and replication below the level necessary to produce 
clinical illness.[9] The lifetime risk of reactivation of latent infection in 
healthy HIV-uninfected individuals is 10%, with 5% developing TB 
during the first 2 - 5 years after infection. The risk is greatly increased 
in the context of immunosuppression, most notably due to HIV 
infection.[3] The WHO estimates that in countries with a generalised 
HIV epidemic, HIV-infected persons have a 20 - 37-fold greater risk of 
developing TB than HIV-uninfected persons. Although antiretroviral 
treatment (ART) reduces the risk of TB by approximately two-
thirds,[10-12] TB remains a common cause of morbidity[13,14] and a 
leading cause of early mortality in individuals on ART.[15]
Purpose of this article
The purpose of this article is to present the evidence to support 
isoniazid preventive therapy (IPT) use, particularly continuous 
IPT (cIPT), in HIV-positive people as part of a combination of TB 
prevention strategies to reduce individual risk of TB and to contribute 
to TB control. Alternative TB preventive therapy regimens for 
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persons living with HIV and preventive therapy for HIV-uninfected 
persons at high risk of TB are also discussed. The paper focuses 
exclusively on TB preventive therapy for adults.
IPT in HIV infection
History of IPT in SA
The IPT guidelines for TST-positive people living with HIV were 
initially incorporated into the SA ART guidelines in 2005. Uptake 
of IPT was poor after introduction of these guidelines, largely due 
to TST creating a programmatic barrier to implementation and 
concerns of generating isoniazid resistance.[16]
In 2010, in line with the WHO recommendations, SA revised its 
national IPT guidelines and removed TST as a requirement to initiate 
IPT, to facilitate programmatic implementation of IPT. The uptake of 
IPT increased dramatically and more than 375 000 South Africans 
living with HIV were started on IPT in 2011 and 2012, respectively, 
making the IPT programme one of the largest in the world. Despite 
this, uptake of IPT among people living with HIV in care, including 
pregnant women, remains poor. The SA IPT guidelines were re-issued 
in 2013 and recommend at least 36 months of IPT for TST-positive 
HIV-infected persons, including people on ART; 6 months of IPT for 
those whose TST status is unknown, regardless of whether they are 
on ART or not; and 12 months of IPT for persons on ART if their 
TST is negative.[17] People living with HIV who are not on and do not 
require ART, and who have a negative TST, do not need IPT.
Screening for TB
Screening for active TB disease is required before commencing IPT to 
minimise the risk of developing drug resistance by inadvertently treating 
active TB with an inadequate regimen. An individual participant meta-
analysis showed that a symptom screen of a cough (any duration), night 
sweats, loss of weight and fever was able to identify HIV-positive people 
with a very low probability of having undiagnosed active TB disease.[18] 
Chest radiography combined with symptom screening increased the 
sensitivity of TB screening, particularly among SA goldminers.[18-20] On 
the basis of these results, the WHO recommends that TB disease among 
people living with HIV be excluded before starting IPT, using a symptom 
screen of current cough, night sweats, fever and weight loss.[21] In HIV 
clinics that routinely screen their patients at every clinic visit, the WHO 
TB symptom screen performs less well, particularly among patients on 
ART.[22] In settings with a high prevalence of undiagnosed TB disease, 
some experts recommend excluding TB by doing a sputum culture or, 
in sick hospitalised patients, using a lateral flow assay for mycobacterial 
lipoarabinomannan on urine combined with Xpert MTB/RIF on sputum 
or urine.[22-24] TB screening before starting IPT may detect TB cases 
earlier, thereby reducing transmission and TB-associated mortality.
Efficacy of 6 - 12 months of IPT
In the most recent meta-analysis of people with HIV, 6 or 12 months 
of IPT was associated with a 32% lower incidence of active TB than 
placebo (relative risk (RR) 0.68; 95% confidence interval (CI) 0.54 - 
0.85).[25] This benefit was greatest among individuals with a positive 
TST (RR 0.38; 95% CI 0.25 - 0.57).[25] IPT was also effective when 
implemented in a routine HIV care programme for SA goldminers, 
prior to ART availability.[26] IPT, given for 6 - 12 months after TB 
treatment, is effective in reducing the risk of recurrent TB disease and 
is recommended by the WHO.[21,27]
IPT with ART
IPT combined with ART reduced the risk of TB disease by 80 - 97% 
and death by up to 50% in HIV-infected persons.[28-31] A recent 
individually randomised, pragmatic, controlled trial demonstrated that 
IPT, taken for 12 months with ART, decreased TB incidence by 37% 
(hazard ratio (HR) 0.63; 95% CI 0.41 - 0.94) overall compared with 
ART alone.[32,33] The effectiveness of IPT was similar when assessed by 
interferon-gamma release assay and TST status.[33] The results of this 
study underpin the current SA guidelines for IPT with ART.
cIPT 
Recent evidence from studies conducted in high-transmission 
settings suggests that cIPT may be beneficial. Among HIV-infected 
participants in Botswana who received 36 v. 6 months of IPT, TB 
incidence was reduced by 43% overall (HR 0.57; 95% CI 0.33 - 0.99); 
among TST-positive participants TB incidence was reduced by 74% 
(HR 0.26; 95% CI 0.09 - 0.80), whereas TST-negative participants 
received no benefit (HR 0.75; 95% CI 0.38 - 1.46).[31] In the per 
protocol analysis, there were no incident cases of TB among TST-
positive persons who took 36 months of IPT. Among TST-positive, 
HIV-infected SA adults, incidence rates of TB or death were similar 
between participants who received cIPT or 6 months of IPT in the 
intention-to-treat analysis (2.7 v. 3.6/100 person-years, incidence rate 
ratio (IRR) 0.75; 95% CI 0.38 - 1.38).[34] In the per protocol analysis, 
the incidence of TB or death was reduced by 58% in the cIPT study 
arm, compared with the 6 months of IPT arm.
Durability of IPT
In the pre-HIV era, IPT was associated with a durable reduction in 
TB incidence in mental institutions and Alaskan villages.[35-38] In the 
HIV pre-ART era, 6 months of IPT in high-transmission settings was 
durable for up to 18 months.[39,40] In the ART era, IPT has limited 
durability in high TB transmission settings.[40,41] In the Botswana trial 
of 6 v. 36 months of IPT, among persons who took 6 months of IPT 
the risk of TB increased approximately 200 days after stopping IPT,[31] 
while among persons who took 36 months of IPT, TB incidence 
increased by 90% after stopping IPT.[42] Among SA goldminers, the 
incidence of TB in the intention-to-treat analysis was reduced by 58% 
during the intended 9-month IPT period. TB incidence increased 
rapidly following cessation of IPT and was similar to that observed 
for those who did not start IPT in the post-treatment period.[43]
Safety of IPT
The safety of IPT was recently confirmed in more than 23 500 SA 
goldminers. With clinical monitoring during the 9 months of IPT, the 
risk of isoniazid-associated adverse events, including clinical hepatitis, 
was low (0.5%), even among older patients and those on ART.[44] In the 
individually randomised trial of IPT with ART v. placebo with ART, 
participants on IPT were 2.13 times (95% CI 0.97 - 4.67) more likely 
to discontinue the study medication due to grade 3 adverse events or 
raised liver enzymes.[32] Among HIV-positive adults in Botswana, the 
risk of severe adverse events and death was similar in the 6-month and 
cIPT groups; however, the risk of death among persons with a negative 
TST was increased, although none of the deaths were attributed to 
isoniazid.[31] Among HIV-infected South Africans taking cIPT (v. 
6 months of IPT), serious adverse reactions were more common 
(18.4 v. 15.4/100 person-years) as was permanent discontinuation of 
treatment (36.5% v. 1.9%).[34] Grade 3 or 4 elevation of aspartate or 
alanine aminotransferase during the treatment phase was much 
more common with cIPT than with 6 months of IPT (28.0% v. 5.5%; 
p<0.001).[34]
Isoniazid resistance
Theoretically, if active TB is missed and the bacterial load is large 
enough, treatment with monotherapy or an inadequate regimen 
has the potential to generate drug resistance. A systematic review of 
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studies of IPT conducted between 1951 and 2005 concluded that IPT 
was not associated with an increased risk of isoniazid resistance and 
that isoniazid resistance is much more likely to result from inadequate 
treatment of active disease.[45] The studies of cIPT in Botswana and 
SA did not show an increased risk of isoniazid resistance.[31,34] Among 
126 goldminers with TB after starting IPT, the prevalence of isoniazid 
resistance and treatment outcomes were similar to those in TB cases 
without previous exposure to IPT.[46] The impact of wide-scale uptake 
of preventive therapy on generating drug resistance is unknown. 
Mathematical modelling suggests that the emergence of isoniazid 
resistance with IPT use may be reduced by delivering IPT to those 
who will benefit the most and by improved case finding and prompt 
treatment of those with drug-resistant TB disease.[47,48]
Population-level effect of IPT
In the pre-HIV era, community-wide IPT was evaluated in Alaska, 
Greenland and Tunisia, all of which had epidemic TB. In Alaska, 
IPT was given to households for 1 year, which reduced the risk of 
TB by 69%.[35] As the intervention was so successful, 12 months of 
IPT was given to both placebo and IPT groups 5 years later, and the 
population-level effect has been durable for more than 3 decades.[36] 
In Greenland and Tunisia, the effect of community-wide IPT was 
modest (31% and 26% reduction in TB incidence, respectively), 
largely owing to an inadequate dose of isoniazid and/or poor 
adherence to IPT in both of the trials.[49,50] The Thibela TB study[51] 
evaluated the effectiveness of community-wide IPT in addition 
to standard of care, compared with standard of care alone, among 
SA goldminers. The intervention, which is unprecedented in the 
history of TB control, included mass screening for TB using chest 
radiography and symptoms, simultaneously linked to treatment for 
active disease or latent infection. Despite reducing the individual risk 
of TB by 58% while participants took the 9-month course of IPT, the 
effect waned soon after stopping IPT and there was no measurable 
reduction in TB incidence or prevalence at a population level after 
the intervention was completed.[43] Mathematical modelling suggested 
that even if the intervention was optimally implemented, a 20% 
reduction in TB incidence at a population level was the most that 
could be expected.[51] The modelling also suggested that cIPT would 
have a profound impact on TB incidence at a population level.[51]
TB after IPT: Possible mechanisms
TB that occurs after IPT may be due to reactivation of inadequately 
treated TB or reinfection with a new strain of TB. Isoniazid impairs 
mycobacterial wall synthesis and is a potent bactericidal drug that 
results in a rapid decline in actively multiplying mycobacteria. A 
recent study showed that isoniazid rapidly killed actively dividing 
M. smegmatus. However, a few cells continued to divide in the presence 
of isoniazid owing to dynamic persistence associated with stochastic 
pulsing of catalase-peroxidase (KatG), which activates isoniazid.[52] 
When isoniazid was withdrawn, the surviving cells underwent 
exponential growth again and were susceptible to isoniazid when it 
was reintroduced, suggesting that they had not developed resistance 
to the drug. It is likely that a similar phenomenon occurs when 
M. tuberculosis is treated with isoniazid. In support of this hypothesis, 
mathematical modelling of the Thibela TB intervention was not able 
to mirror the observed data unless the model assumed that IPT does 
not cure LTBI. If the model is correct and IPT does not cure LTBI, 
reactivation of inadequately treated LTBI after stopping treatment 
may in part explain the lack of durable benefit. In high-transmission 
settings, reinfection with a new strain of TB has been shown to be an 
important cause of recurrent TB disease after successful completion 
of treatment in HIV-infected and HIV-uninfected TB patients.[53,54] 
In settings with a high annual risk of infection such as SA (estimated 
at 4.7% per year), it is likely that reinfection will contribute to the 
limited durability of IPT. In high-burden settings, both reactivation 
of inadequately treated LTBI and reinfection are likely to limit the 
durability of IPT. Regardless of the mechanism of TB after IPT, cIPT 
will reduce the risk of TB in persons living with HIV.[31,42]
Alternative TB preventive therapy 
regimens
Efficacy of alternative preventive therapy regimens
Alternative TB preventive therapy regimens have also been evaluated 
in people living with HIV. A meta-analysis of TB preventive therapy 
regimens found rifampicin-containing regimens (rifampicin and 
pyrazinamide; isoniazid and rifampicin; isoniazid, rifampicin and 
pyrazinamide) not to be more effective than IPT alone.[25] In the 
pre-ART era, however, the rifampicin-based regimens were shown to 
have a more durable effect than isoniazid alone.[40,41]
A novel regimen of intermittent high-dose isoniazid and 
rifapentine given weekly for 3 months has recently been evaluated 
in low and high TB burden settings. Rifapentine is a rifamycin with 
a long half-life and greater potency against M. tuberculosis than 
rifampicin. In mouse models of LTBI, rifapentine had a greater 
sterilising effect than isoniazid,[55] and weekly high-dose rifapentine 
and isoniazid for 3 months (3HP) had greater efficacy than 
isoniazid alone.[56] The TB Trials Consortium Study 26[57] compared 3 
months of high-dose once-weekly isoniazid (900 mg) and rifapentine 
(900 mg) (3HP) with 9 months of daily isoniazid (300 mg) (9H) 
in a non-inferiority study design.The study was conducted in low 
to medium TB and HIV burden settings (USA, Canada, Brazil and 
Spain). Eligible participants aged 2 years and above were enrolled 
into the study, regardless of HIV status. The study showed that 
3HP was non-inferior to 9H in the modified intention-to-treat and 
per protocol analysis, and there was a trend towards superiority in 
reducing TB incidence (9H: 16/100 person-years; 3HP: 7/100). The 
3HP study arm had a higher treatment completion rate than the 9H 
arm (82% v. 69%).[57] As few HIV-infected persons were enrolled 
into Study 26 (2.6% HIV-infected), an ancillary study was conducted 
to evaluate safety, tolerability and efficacy of 3HP in HIV-infected 
adults. Among 399 HIV-infected persons (193 9H, 206 3HP), 3HP 
was non-inferior to 9H, with cumulative TB incidences in the 3HP v. 
the 9H arm of 1.01 and 3.69/100 person-years, respectively.[58,59] 3HP 
compared with 9H in HIV-infected persons was tolerable and had 
higher completion rates (88% v. 64%).[58,59]
The 3HP regimen was also compared with 6 months of IPT (6H) 
in HIV-infected, ART-naive (at enrolment), TST-positive SA adults. 
In the intention-to-treat analysis, the incidence rates of active TB or 
death in the 3HP and 6H arms were similar (3.1 v. 3.6/100 person-
years, respectively, crude IRR 0.87 (95% CI 0.54 - 1.39)).[34] Based 
on the results of TB Trials Consortium Study 26, the US Centers for 
Disease Control (CDC) issued recommendations for the use of the 
3HP regimen for the treatment of LTBI.[47] The CDC is currently 
evaluating self-administered, as opposed to directly observed, 3HP.
Safety of alternative preventive therapy regimens
Rifampicin-based regimens (rifampicin and pyrazinamide; isoniazid 
and rifampicin; isoniazid, rifampicin and pyrazinamide), compared 
with IPT, in people with HIV are associated with a greater rate of 
treatment discontinuation due to adverse effects.[25] In Study 26 
participants, the vast majority of whom were HIV-uninfected, there 
was reduced drug-related hepatotoxicity in the 3HP study arm 
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compared with the 9H arm (0.4% v. 2.7%), but rates of permanent 
discontinuation due to an adverse event were higher (4.9% v. 3.7%).[57] 
In the follow-on trial to Study 26 among HIV-infected persons taking 
3HP v. 9H, the rates of drug discontinuation due to adverse drug 
reactions were similar (3.4% v. 4.2%).[58,59] Among HIV-infected, TST-
positive adult South Africans taking 3HP v. 6 months of IPT, grade 3 
or 4 hepatotoxicity (elevated alanine or aspartame aminotransferase) 
occurred less commonly in the 3HP study arm (1.5% v. 5.5%, 
respectively), and the rates of permanent discontinuation of the study 
drug were similar (1.8% v. 1.9%, respectively).[34]
TB preventive therapy for HIV-
uninfected persons at high risk of TB
TB preventive therapy is recommended for HIV-uninfected persons 
who are receiving chemotherapy or anti-tumour necrosis factor 
(TNF) therapy and are at increased risk of developing TB. The 
South African Rheumatism and Arthritis Association recommends 
a regimen of either isoniazid or rifampicin for 3 months or IPT for 
6 - 9 months for TST-positive persons prior to starting anti-TNF 
drugs. Silicosis is an occupational lung disease that results from 
chronic silica dust exposure and is associated with an approximately 
threefold greater risk of TB than in silica-exposed workers who do 
not have silicosis. The National Department of Health has included 
recommendations for HIV-uninfected persons with silicosis in the 
2013 IPT guidelines: 36 months of IPT if TST-positive; 6 months 
IPT if TST unknown; no IPT if TST-negative. For people living with 
HIV and silicosis, the IPT guidelines for people living with HIV 
should be followed.
Combination TB prevention:  
The role of IPT
The WHO recommends IPT for people living with HIV as part of 
a combination of TB prevention strategies that include infection 
control to reduce exposure to TB, intensified case finding to detect 
cases earlier, and ART to reduce vulnerability to TB, in addition to 
reducing the numbers lost to follow-up prior to starting TB treatment 
and reducing the time to starting TB treatment.[21,60-62] However, 
implementation of these strategies has been poor. Mathematical 
modelling has suggested that high coverage of IPT, particularly if it 
is given continuously and in combination with other treatment and 
prevention strategies, will contribute to TB control and accelerate 
progress towards elimination of the disease.[51,63,64]
Conclusion
IPT is safe, does not generate isoniazid resistance, and reduces the 
risk of TB among persons living with HIV, particularly if given 
continuously to those with evidence of TB infection. Continuous 
IPT should be used in combination with other TB treatment and 
prevention strategies to contribute to TB control. Alternative TB 
preventive therapy regimens may be considered for certain patients 
at high risk of TB.
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